A recent study in eClinicalMedicine found that fecal microbiota transplantation, combined with fruquintinib and tislelizumab, significantly improved survival rates in patients with microsatellite stable metastatic colorectal cancer, showing manageable safety and notable increases in progression-free and overall survival.